Lord, Abbett & Co
ALLO icon

Lord, Abbett & Co’s Allogene Therapeutics ALLO Stock Holding History

Lord, Abbett & Co’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-450,863
Closed -$17M – 651
2020
Q3 		$17M Buy
+450,863
New +$17M 0.05% 402
2019
Q4 		– Sell
-334,964
Closed -$9.13M – 662
2019
Q3 		$9.13M Sell
334,964
-44,567
-12% -$1.27M 0.03% 544
2019
Q2 		$10.2M Buy
379,531
+1,615
+0.4% +$45K 0.03% 543
2019
Q1 		$10.9M Sell
377,916
-24,086
-6% -$699K 0.04% 543
2018
Q4 		$10.8M Buy
+402,002
New +$10.7M 0.04% 522

Other funds holding ALLO

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Lord, Abbett & Co's ALLO Position: Q4 2020 in Review

Lord, Abbett & Co sold out of Allogene Therapeutics (ALLO) in Q4 2020, closing a stake of 450,863 shares — an estimated $17M sold.

Lord, Abbett & Co first reported a position in ALLO in Q4 2018 and held it in 5 quarters. The position peaked at $17M in Q3 2020. 165 funds tracked by Wall St. Rank hold ALLO as of Q4 2020.

  • Lord, Abbett & Co reported no remaining Allogene Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Lord, Abbett & Co sold 450,863 Allogene Therapeutics shares in Q4 2020, an estimated $17M.
  • Lord, Abbett & Co first reported a position in Allogene Therapeutics in Q4 2018 and held it in 5 quarters.
  • Lord, Abbett & Co's Allogene Therapeutics position peaked at $17M in Q3 2020.
  • 165 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2020.

Based on Lord, Abbett & Co's 13F filing for Q4 2020, filed 9 Feb 2021.